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Figure 1. Schematic displaying a general 













Figure 3. Gene insertions into the phage genome elongate the 
phage particle. The phage accomplishes this by producing and 





Figure 4. Structure of pIII and 
fusion points for display on phage. 
The CT domain (residues 257-
406) is embedded in the phage 
particle, while the N domains (N1; 
residues 1-68, and N2; residues 
87-217) are exposed. Glycine-rich 
linker regions connect the three 
domains (Gly1 and Gly2). 
Positions 198 and 249 are typical 
positions for protein of interest 


















Figure 5. Comparison of phage and phagemid vector cloning for pIII display. Target 
protein sequences are inserted before gene III. Both vector methods carry a phage 
replication origin (Ff) to permit phage genome replication. Phagemid vectors also 
carry a plasmid origin of replication, and an antibiotic resistance marker. Helper 
phage facilitates viral protein expression, but is packaging-deficient and does not 
compete with the phagemid genome during assembly. In this experiment, 
monovalent phage display is preferred as it reduces the avidity effects that plague 


















Figure 6. Schematic displaying oligonucleotide-directed mutagenesis. a) A synthetic 
oligonucleotide is annealed to a single-stranded DNA template that has a significant 
amount of thymine bases replaced by uracil (ss-DNA). The oligonucleotide contains 
a degenerate codon, and is designed to encode mutations (*). b) A double-stranded 
DNA (CCC-dsDNA) is synthesized by polymerase and ligase. c) The CCC-dsDNA is 
then transformed into E. coli cells where it is replicated to either the mutant or wild-





























Figure 7. Illumina high throughput sequencing scheme. 1) Multiple DNA sequences 
are extracted from selected phage. 2) Sequences are fragmented. 3) Each set of 
fragments is labelled with a tag. 4) Fragments are simultaneously sequenced. 5) 








Figure 8. Sample high throughput 
sequencing maps. Maps display the 
frequency of reads of a specific amino 
acid mutation at a specific position in 
the target protein for the variant library 
after zero (initial library), three, and six 
three rounds of selection, respectively. 












Figure 9. Cancer-related impacts of oncogenic RAS. Table 


























Figure 10. RAF-RBD contact points with the RAS effector domain. Image 





Figure 11. The RAF-MEK-ERK kinase cascade signaling 









Figure 12. RAS initiated RAF-MEK-MAPK signaling pathway in the 













Figure 14. Schematic displaying Aim 1 selection. The phage displayed RAF variant 
library is selected for RAS binding function via biotinylated RAS, which binds to 
















Figure 15. RAF mutations with known negative 
impacts on RAS binding affinity. This will be used as 
an additional validation of the library of RAF mutants. 
Variants that bind RAS should not contain any of 







Figure 16. Schematic displaying Aim 2 selection strategy. The phage displayed RAF 
variant library undergoes two rounds of selection for RAS binding: in the absence 
and presence of Rigosertib, the RAS mimetic inhibitor. Both sets of selected mutants 






Figure 17. Sample sequence logo. DNA sequences are aligned and used to create 
a sequence logo that highlights conserved nucleotides. This technique will be used  
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